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Abstract 
Long-term survival after childhood cancer has improved dramatically over recent decades but 
survivors face lifelong risks of adverse health effects. Many of these chronic conditions are a 
direct result of previous therapeutic exposures. Compared to their siblings, survivors face a 
greater than 8-fold increase in relative risk of severe or life-threatening medical conditions; 
the most significant of these include second malignancies and cardiovascular and pulmonary 
diseases. Imaging can play a key role in identifying and characterizing such complications, 
which can be reasonably predicted with knowledge of the child’s treatment. This article 
highlights the varied radiologic presentations and features seen in late cancer-therapy-related 
conditions. 
 
Keywords Cancer therapy, Children, Computed tomography, Late effects, Magnetic 
resonance imaging, Radiography, Toxicities 
 
Introduction 
Long-term survival after childhood cancer has improved dramatically over recent decades, 
with 5-year survival rates ranging from 64% to 97% [1] compared to 45% in the mid-1970s 
[2]. Despite such encouraging statistics, survivors face an increased lifelong risk of adverse 
health effects [3, 4], many of which stem directly from their previous therapeutic exposures 
[5]. Results from the Childhood Cancer Survivor Study (CCSS) have shown that compared 
with their siblings, survivors face an 8.2-fold increased relative risk for a severe or life-
threatening condition, with cumulative incidence of chronic conditions reaching 73.4% at 30 
years after diagnosis [6]. 
The late effects can affect all organ systems (Table 1), but the most severe conditions 
include second malignancies and cardiovascular and pulmonary diseases [7–10]. The 
Blinded Manuscript Click here to view linked References
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Children’s Oncology Group (COG) has developed risk-based, exposure-related guidelines for 
follow-up care in childhood cancer survivors [11]. Radiology plays a key role in both 
identifying and characterizing complications, most of which can be reasonably predicted with 
knowledge of the type of treatment received [12].  
This article serves as a companion piece to our review on acute and subacute 
toxicities of cancer therapies in children [13]. This article highlights the radiologic 
appearances of late cancer-therapy-related, non-neurological conditions, defined as those 
occurring at least 1 year after the conclusion of therapy. Some complications, although not 
strictly diagnosed by imaging, are also described for their secondary radiologic features. 
Table 1 provides a general overview of the various organ systems involved, and the more 
commonly seen entities are described in further detail in this article. 
 
Multisystem complications 
Chronic graft-versus-host disease  
Allogenic hematopoietic stem cell transplantation (HSCT) is a well-established treatment for 
some hematologic malignancies [14]. The incidence of chronic graft-versus-host disease 
(GVHD) following HSCT in children ranges from 6% when the stem cells are infused from a 
matched sibling to 65% when they are provided by a matched unrelated donor [15]. Chronic 
GVHD is no longer defined based on the time after HSCT (historically, >100 days after 
transplantation), but according to specific clinical and functional criteria that suggest immune 
dysfunction, none of which relies upon imaging features [16]. The median onset of chronic 
GVHD after HSCT is approximately 6 months and onset is usually not seen after 3 years 
post-transplantation [16]. Acute GVHD typically involves skin, liver and gastrointestinal 
tract. However, chronic GVHD can involve any organ system. Imaging manifestations of 
chronic GVHD include gastrointestinal strictures, findings that mimic primary sclerosing 
cholangitis (PSC) and bronchiolitis obliterans [17]. Although PSC-like changes have been 
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described in experimental chronic GVHD in a mice model [18], this has not been reported in 
children (Fig. 1). It is estimated that 80% of people with chronic GVHD have liver 
involvement [19] and if a biopsy is required to confirm diagnosis, an interventional 
radiologist might be asked for assistance. 
 
Second malignant neoplasms 
Second malignant neoplasms are defined as “histologically distinct malignancies developing 
after completion of treatment for the primary malignancy” [20]. They are the most frequent 
cause for non-relapse late mortality in survivors [21], who have a 3- to 6-fold increased risk 
of malignancy compared to the general population [22]. The risk of developing a second 
malignant neoplasm has been estimated to be 10% at 20 years and 26% at 30 years age [23], 
although this risk varies with the type of primary cancer diagnosis (there is a higher risk in 
hereditary retinoblastoma [24] and Hodgkin lymphoma survivors [25]), therapy received and 
underlying genetic predisposition (e.g., Li–Fraumeni syndrome). 
Post-treatment solid tumors are more strongly associated with radiation therapy, 
whereas those associated with chemotherapy (typically alkylating agents or topoisomerase II 
inhibitors) include myelodysplasia and acute myeloid leukemia [26]. Solid second malignant 
neoplasms include breast (the most common second malignant neoplasm in the CCSS cohort 
[27]), thyroid, brain and bone tumors [22] (Fig. 2). In general, the higher the radiation dose 
received and the younger the age at treatment, the greater the risk for developing solid second 
malignant neoplasms. 
Imaging is used for surveillance in selected subgroups such as those with a cancer 
predisposition syndrome [28]. Whole-body MRI is a radiation-free technique to screen for 
these neoplasms. Periodic whole-body MRI might be performed in children with Li–
Fraumeni syndrome for development of any neoplasm because they are predisposed to cancer 
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development [28]. Girls who get chest radiation are at increased risk for subsequent breast 
cancer. The Children’s Oncology Group recommends initiation of screening 
MRI/mammography at age 25 or 8 years after radiation, whichever is later [12]. 
 
Endocrine dysfunction 
Thyroid 
The thyroid gland may be included within the radiation field when treating head and neck 
tumors, or during cranio-spinal irradiation. Hypothyroidism is the most common thyroid 
disorder following radiotherapy [29] and can also occur after HSCT [30]. However, even 
when this condition is present, the thyroid gland can still look normal on sonography. 
Histopathological changes of an irradiated thyroid gland include follicular degeneration, 
stromal atrophy and obliteration of underlying vasculature [31]. Sonographic features of the 
irradiated thyroid gland can include diffuse atrophy, solitary or multiple nodules (which may 
be malignant), cysts (simple and complex) and heterogeneity within the thyroid tissue [32] 
(Fig. 3). Differentiating malignant from benign nodules sonographically can be difficult, but 
features concerning for malignancy include the presence of microcalcifications and irregular 
margins, and absence of a uniform hypoechoic halo around the nodule [33]. Even though a 
hypoechoic halo has 95% specificity for a benign thyroid nodule, a halo is not seen in >50% 
of benign nodules [33]. Also, 10–24% of papillary thyroid carcinomas have either a complete 
or incomplete halo around them [33]. 
 
Growth 
Cranial irradiation can damage the hypothalamic-pituitary axis, leading to gonadotropin or 
growth hormone deficiency at high dosages, and precocious puberty at lower dosages [34-
37]. The age of pubertal onset has been shown to be particularly important in determining 
final height, with younger children being at greater risk of developing precocious puberty and 
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therefore eventual shorter stature [38]. Growth hormone deficiency can be seen in children 
who received total body irradiation in preparation for bone marrow transplantation [39]. The 
radiologist might be asked to review a child’s bone age to determine the degree of bone delay 
or advancement. Knowledge of this late effect can also be helpful to the radiologist reviewing 
a skeletal survey for short stature. 
 
Pulmonary complications 
Significant long-term pulmonary dysfunction, as determined by pulmonary function tests 
(PFT), can be seen in survivors after therapy [40, 41]. These effects are more likely to occur 
if children receive both chemotherapy and radiation, and can be seen in up to 72% of cases 
[26]. Pulmonary late effects include pulmonary fibrosis, interstitial pneumonitis, and 
restrictive/obstructive lung diseases. In children surviving 5 years or more, the CCSS [42] 
found a significant association between cancer therapy and lung fibrosis, recurrent 
pneumonia and pleurisy. The strongest association of pulmonary damage was demonstrated 
between radiotherapy and pulmonary fibrosis. However, pulmonary toxic chemotherapy 
agents such as bleomycin, busulfan, lomustine (CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-
nitrosourea]) and carmustine (BCNU [bis-chloroethylnitrosourea]) also contributed to 
developing fibrosis. Chest CT is useful for detecting pulmonary fibrosis, bronchiolitis 
obliterans and bronchiolitis obliterans organizing pneumonia (BOOP). Pulmonary fibrosis 
involves the part of the lung included in the radiation field (Fig. 4). Typical fibrotic changes 
can be seen in the medial aspects of both lungs in Hodgkin lymphoma survivors who 
received mediastinal radiation. Non-pulmonary findings, such as simple thymic cysts, can 
also occur as a result of chemotherapy or radiation. If large, these can mimic tumor 
recurrence [43]. 
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Cardiovascular complications 
Congestive cardiac failure and cardiomyopathy are well-recognized complications from prior 
anthracycline chemotherapy or chest radiation [44]. This is of particular concern because 
approximately 60% of survivors might have been exposed to one of these therapies [10]. 
They face a 15-fold increased risk of heart failure [6] compared to the general population. 
The condition is progressive and can be clinically silent for years [45]. For this reason several 
oncology groups worldwide advocate lifelong screening with echocardiography and clinical 
assessment every 1–5 years, depending on cumulative anthracycline dose exposure, radiation 
to a field that included the heart, and age at therapy [46]. Chest radiographs might 
demonstrate cardiomegaly with or without signs of cardiac failure (Fig. 5), but the imaging 
modality of choice for screening for cardiomyopathy is echocardiogram.  
 
Gastrointestinal complications 
Enteric 
Chronic radiation enteropathy typically occurs 6–24 months post radiotherapy [31]. It can 
manifest as mucosal ulceration, stricture formation, malabsorption or bowel obstruction [47] 
(Fig. 6); the last is reported to occur in 36% of survivors [48].  
Surgical intervention for the primary malignancy can also result in subsequent 
adhesion formation. If resection of previously irradiated bowel is later needed, there is a high 
incidence of anastomotic dehiscence, re-obstruction and even mortality [49]. 
 Esophageal strictures (Fig. 7) and acquired tracheoesophageal fistulas can also be 
seen in children treated with radiation or chemotherapy [50]. However, these are rare and 
more commonly associated with non-malignant causes, like foreign body ingestion, severe 
mucositis and candida esophagitis [51, 52]. 
 
Hepatobiliary 
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Focal nodular hyperplasia 
Focal nodular hyperplasia (FNH) is a non-malignant entity seen with increasing frequency in 
children following treatment with chemotherapy, HSCT or radiation [53–55]. The interval 
between cancer diagnosis and discovery of FNH ranges 2–12 years with median interval of 
6.7 years [56]. A liver lesion might initially be identified on sonography but FNH can be 
diagnosed with greater confidence and accuracy by liver MRI [57] (Fig. 8). FNH in cancer 
survivors tends to be multiple, small (<3 cm) and atypical, with lack of a central scar. The use 
of MRI with hepatocyte-specific contrast media like gadobenate helps to differentiate FNH 
from metastases [58].   
 
Hemochromatosis 
Iron overload is common in cancer survivors who have received multiple red blood cell 
transfusions and is associated with hepatic, cardiac and endocrine dysfunction. Siderosis can 
be histologically identified in up to 70% of children near the end of their treatment for acute 
lymphoblastic leukemia [59–61], and hepatic iron overload can be reliably diagnosed and 
approximately quantified by MRI [62–64] (Fig. 9).   
 
Hepatosteatosis 
Fatty infiltration of the liver can occur for several reasons in childhood cancer survivors, such 
as from immunosuppressive chemotherapeutic agents; in survivors of hepatoblastoma treated 
with liver transplantation [65], or as part of a metabolic syndrome in cancer survivors 
secondary to late effects of hyperlipidemia, insulin resistance from total whole-body 
irradiation, and bone marrow transplantation [66]. Fatty infiltration results in increased 
echogenicity of the hepatic parenchyma on sonography. Fatty infiltration can be reliably 
diagnosed with in- and out-phase imaging on MRI.   
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Hepatobiliary toxicity 
Limited data exist on late effects of chemotherapy on the liver but hepatobiliary dysfunction 
is thought to be related to prior anti-metabolite agent therapy (e.g., methotrexate, 6-
mercaptopurine) and after HSCT [67]. Delayed hepatic injury might not be preceded by 
clinically apparent acute toxicity before leading to hepatic fibrosis. Fibrosis places the child 
at risk of developing portal hypertension, cirrhosis and hepatocellular carcinoma [68]. 
Radiation-induced hepatic damage is uncommon in cancer survivors unless predisposing 
conditions (e.g., viral hepatitis, iron overload) are present [69]. In our experience, nonspecific 
increased echogenicity and heterogeneity of hepatic parenchyma are commonly observed on 
US in cancer survivors, which could represent some form of hepatic damage.  
 
Genitourinary system complications 
Therapy-related late effects on kidneys include radiation nephropathy, renal atrophy (with 
focal or diffuse parenchymal and functional loss [70]; Fig. 10) and end-stage renal disease 
(ESRD) as a result of radiation or nephrotoxic chemotherapeutic agents (such as cisplatin  
[71] and ifosfamide [72]). These toxicities are generally observed 6 months or more after 
treatment [73].  
Bladder fibrosis can develop from radiotherapy or chemotherapy (particularly 
cyclophosphamide), resulting in interstitial fibrosis of the bladder wall. Urgency and 
frequency from reduced bladder capacity are common symptoms. Imaging, though rarely 
used to make the diagnosis, might demonstrate a contracted and poorly distensible bladder, 
sometimes accompanied by hydronephrosis [74]. Fistula formation to adjacent bowel loops 
rarely occurs in children but is more common in adults after brachytherapy [70]. 
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Gonadal dysfunction is the most severe long-term effect in cancer survivors, 
especially after alkylating agents and pelvic radiotherapy [64]. Hypothalamic-pituitary axis 
disorders also result in impaired fertility in cancer survivors [10, 75, 76]. Ovarian 
transposition outside the radiation field, usually superiorly in the abdomen, is sometimes 
performed prior to radiotherapy to minimize radiation damage to the ovaries in children with 
pelvic cancers [77] (Fig. 11).  
 
Musculoskeletal complications 
Bone growth deformity 
Radiotherapy, chemotherapy and surgery have all been associated with long-term 
musculoskeletal effects independently and additively [78]. Radiation therapy can affect 
chondroblast and chondrocyte proliferation with reduction in bone growth; soft-tissue 
hypoplasia can also result. Scoliosis is thought to be sometimes caused by radiation-induced 
asymmetrical growth plate impairment (Fig. 12). Chances of spinal malalignment increase 
with younger age at exposure, higher doses, and asymmetrical radiation [78]. Bony 
hypoplasia, especially involving flat bones, can result from inhibition of osteogenesis by 
radiation [78]. Severe facial deformity has been noted in up to 30% of children who received 
radiation for head and neck rhabdomyosarcoma [79]. Growth disturbances affecting hips and 
pelvis include hemiatrophy of the pelvis (Fig. 13), slipped capital epiphyses (Fig. 14) and 
osteonecrosis of the femoral head. Other effects include leg-length discrepancy and muscular 
atrophy [78, 80, 81]. Radiographs play an important role in assessment of these abnormalities 
related to bone growth and could be sufficient in most cases.  
 
Bone mineral density changes 
Treatment with corticosteroids, methotrexate and radiotherapy has been implicated in altered 
bone remodeling [82] and reduction in bone mineral density, predisposing patients to 
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pathological fractures [30] (Fig. 15). The incidence of bone mineral density deficits may be 
as high as 45% in cancer survivors [83]. 
Radiation osteitis is typically witnessed 1 year after therapy [81] and can be difficult 
to differentiate from residual or metastatic bone disease. As irradiated bone heals, osteoid 
deposits can form, resulting in a coarsened trabecular matrix pattern with disorganized 
sclerosis (Fig. 16).  
 
Bone tumors 
Osteochondromas are the most common secondary bone tumor to develop within a radiation 
field. Their incidence is 1–2% in the general population but 6–20% in children treated with 
radiation therapy (Figs. 17 and 18). The propensity for malignant degeneration is rare and not 
thought to be greater than that in the general population [84, 85]. 
Radiation-induced bone sarcomas, in particular osteosarcomas, can develop in cancer 
survivors [86]. The risk increases significantly in children with cancer predisposition 
syndromes such as retinoblastoma and Li–Fraumeni syndrome. The mean latency period for 
developing malignant bone tumors is about 10 years [87]. The presence of an enhancing soft-
tissue mass associated with bone destruction seen on MRI helps to differentiate second 
malignancy bone sarcoma from radiation changes and infections.  
 
Other effects 
Methotrexate-induced osteopathy radiographically appears very similar to scurvy, with 
osteoporosis, decreased mineralization and fractures [88]. Dense metaphyseal bands of long 
bones, within epiphyseal ossification centers, anterior rib ends, sternum and spine have been 
reported in children receiving pamidronate for bone pain in metastatic osteosarcoma [89]. 
 
Conclusion 
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The late effects of cancer therapy in children can affect all organ systems of the body and can 
cause early mortality. This article has highlighted many of the long-term sequelae that can be 
evaluated by imaging. With increase in long-term survival rates of childhood cancer patients, 
recognition of these radiologic findings is of vital importance to both pediatric and adult 
radiologists. 
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Legends 
Fig. 1 Chronic graft-versus-host disease (GVHD) with liver involvement in a 7-year-old boy 
post hematopoietic stem cell transplantation for acute lymphoblastic leukemia. a, b Axial T2-
W MR images of the liver demonstrate increased periportal signal (a, arrows) and dilatation 
of extrahepatic bile duct (b, arrowhead). c High-resolution US image of the porta hepatis 
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demonstrates common bile duct (arrowhead) with wall thickening and luminal dilatation 
(calipers). Findings of increased periportal signal, duct dilatation and duct wall thickening 
seen in this child with biopsy-proven chronic GVHD resemble those seen in primary 
sclerosing cholangitis  
Fig. 2 Second malignant neoplasm. Osteosarcoma of the right iliac crest in a 14-year-old girl, 
9 years post radiotherapy for treatment of a pelvic rhabdomyosarcoma. a Anteroposterior 
pelvic radiograph reveals increased bony sclerosis and periosteal reaction on the medial 
aspect of the right iliac bone (arrow). b, c MRI. Coronal short tau inversion recovery (b) and 
axial T1-W fat-saturated post-contrast (c) images demonstrate a large, heterogeneously 
enhancing soft-tissue lesion within the area of concern (arrows) 
Fig. 3 Thyroid complications. Thyroid nodules after radiation treatment for a nasopharyngeal 
rhabdomyosarcoma in a 10-year-old girl. Color Doppler US image of the right lobe of the 
thyroid gland 4 years after therapy demonstrates a thyroid nodule with hypoechoic halo 
(arrow), favored as benign in origin  
Fig. 4 Pulmonary sequelae. Pulmonary fibrosis in a 14-year-old girl who 6 years prior had 
resection and radiation treatment for thoracic left paraspinal sarcoma. Axial (a) and coronal 
(b) CT images of the lung demonstrate areas of fibrosis, traction bronchiectasis and volume 
loss in the superior segment of the left upper lobe (arrows), which was in the radiation field  
Fig. 5 Cardiomyopathy. Dilated cardiomyopathy in a 15-year-old girl with history of acute 
myeloid leukemia and treatment with anthracycline. Anteroposterior radiograph of the chest 
demonstrates moderate to marked cardiomegaly. A left ventricular assist device (arrow) has 
been placed to treat the cardiac dysfunction. A mediastinal pigtail drainage catheter, right 
central venous line and nasogastric tubes are seen  
Fig. 6 Radiation enteropathy in a 7-year-old girl with a history of ruptured pelvic 
rhabdomyosarcoma necessitating embolization, radiotherapy and intestinal diversion and 
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formation of loop ileostomy within the right upper quadrant 1.5 years earlier. Anteroposterior 
projection of the pelvis obtained during a fluoroscopic loopogram via the distal ileostomy 
stoma demonstrates narrowing and poor distension of the distal transverse, descending and 
sigmoid colon, and rectum. Note the embolization coils within the right lower quadrant 
(arrow) and presence of calcified gallstones in the right upper quadrant. There is diffuse 
demineralization and coarse trabeculation of the visualized bones 
Fig. 7 Radiation esophagitis resulting in esophageal narrowing and stricture formation in a 
16-year-old boy who had been treated with mediastinal radiation and five cycles of 
chemotherapy at age 8 years for Hodgkin lymphoma. Lateral projection of a water-soluble 
contrast esophagram demonstrates long-segment smooth stricture in the mid-thoracic 
esophagus (arrow)  
Fig. 8 Hepatic complications. Focal nodular hyperplasia in a 5-year-old boy who was 
previously treated with chemotherapy and bone marrow transplantation for neuroblastoma. a, 
b Axial MRI. The liver lesions (arrows) are slightly bright on T2-weighted image (a) and 
remain iso- to hyperintense to liver parenchyma on the hepatobiliary phase 45 min post 
gadobenate contrast administration (b)  
Fig. 9 Iron deposition in a 12-year-old boy with disseminated pineoblastoma and hepatic 
metastases (arrows) as seen on (a) out-phase short echo time (TE) MRI and (b) in-phase long 
TE MRI. Compared to the out-phase image with short TE (a) the liver and spleen lose signal 
on in-phase MR image with longer TE  (b), suggestive of siderosis 
Fig. 10 Marked renal atrophy in a 10-year-old boy was diagnosed at 2 years of age with right 
adrenal neuroblastoma and was treated with surgery, chemotherapy and radiotherapy. a 
Coronal reformatted post-intravenous-contrast CT image demonstrates a small right kidney 
(arrow) with cortical thinning and loss of parenchymal volume. The kidney was normal at the 
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time of tumor diagnosis. b Nuclear medicine study, posterior projection, to assess the boy’s 
glomerular filtration rate demonstrates total loss of function in the right kidney (arrow)  
Fig. 11 Gonadal dysfunction. Ovarian transposition in a teenage girl treated with radiotherapy 
for pelvic Hodgkin lymphoma. a Axial post-intravenous-contrast CT image demonstrates left 
pelvic lymphadenopathy (arrowheads), right ovary (arrow) and left ovary (dashed arrow). b 
Axial post-intravenous-contrast CT image after the ovarian transposition demonstrates left 
ovary now placed on the right side (dashed arrow and outlined by blue line) to prevent 
radiation exposure. c Axial non-contrast CT image shows radiotherapy planning. The thick 
red line outlines the target volume and the thin lines are doses of 5 Gy (purple), 15 Gy (teal) 
and 25 Gy (yellow) 
Fig. 12 Scoliosis in a 12-year-old girl with recurrent mesoblastic nephroma and treatment 
with surgery and radiation. a Axial CT image of the abdomen on day 2 of age demonstrates a 
large heterogeneously enhancing right renal mass (arrowheads). b Posteroanterior radiograph 
of the spine at the age of 12 years shows levoconvex scoliosis of the lumbar spine (arrow) 
Fig. 13 Pelvic hemiatrophy in a 19-year-old man with history of right femoral Ewing 
sarcoma treated with surgery and radiation at the age of 7 years. Pelvic radiograph 
demonstrates a significantly smaller iliac bone compared to the normal left side. The man had 
undergone a limb-sparing procedure of the right femur with placement of bone graft and 
orthopedic hardware (arrows) in the visualized right upper thigh, replacing the femur 
Fig. 14 Slipped capital femoral epiphysis in a 12-year-old girl with history of radiation for 
left pelvic rhabdomyosarcoma 7 years prior. Anteroposterior (a) and frog-leg (b) projections 
of the pelvis show left slipped capital femoral epiphysis, with some deformity of the 
epiphysis (arrows). Note also the atrophy of left pelvic bone  
Fig. 15 Compression fractures in a 30-year-old man with a history of acute lymphoblastic 
leukemia treatment. Lateral CT scout image of the spine shows multilevel vertebral 
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compression fractures and endplate depression with decrease in bone mineral density. His 
bone mineral density Z-score by quantitative computed tomography (QCT) was –1.91 
Fig. 16 Radiation osteitis in a 14-year-old  boywho had previous radiotherapy for Ewing 
sarcoma centered within the right inferior pubic ramus bone (arrows). a, b Anteroposterior 
pelvic radiographs taken during the primary diagnosis at 8 years of age (a) and at age of 14 
years (b) demonstrate progressive right iliac atrophy, heterogeneous sclerosis at the right 
acetabulum, shortened right femoral neck and loss of height of the right proximal femoral 
epiphysis. c Coronal CT with bone windows obtained at age 13 years better demonstrates the 
bony changes in the right acetabulum and proximal femur (arrow) 
Fig. 17 A small osteochondroma in an 8-year-old girl previously treated with craniospinal 
irradiation for medulloblastoma. a Axial CT with soft-tissue windows demonstrates a small 
osseous lesion (arrow) extending into the spinal canal at the T7–8 level, with mass effect on 
the thecal sac, although not causing any spinal cord compression. b T1-W fat-saturated post-
contrast axial MR image at the same vertebral level reveals rim enhancement of the lesion 
(arrow) in keeping with the cartilaginous cap of the osteochondroma 
Fig. 18 A distal femoral osteochondroma in a 12-year-old boy 7 years post radiotherapy for 
stage IV neuroblastoma. Anteroposterior (a) and lateral (b) radiographs of the right knee 
demonstrate a small osteochondroma on the posterior medial aspect of the distal femur 
(arrows). There are coarse bony trabeculations of the metaphyses with underlying 
demineralization 
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Table 1 Late non-neurological complications of cancer therapy in children by organ system 
Organ system Late effects of treatment 
Multisystem 
 
Chronic graft-versus-host disease (GVHD) commonly mimicking 
sclerosing cholangitis; bronchiolitis obliterans (associated with allogeneic 
hematopoietic stem cell transplant [HSCT])  
 
Second malignant neoplasms — breast, thyroid, brain and bone tumors 
(associated with radiation therapy), acute myeloid leukemia and 
myelodysplasia (associated with chemotherapy) 
 
Endocrine 
 
 
Thyroid 
Hypothyroidism, thyroid nodules, hyperthyroidism, thyroid carcinoma 
(commonly associated with radiotherapy or HSCT) 
 
Gonads 
Azoospermia, delayed puberty, absence of secondary sex characteristic 
development, decreased fertility, infertility (can be caused by pelvic 
radiotherapy or exposure to alkylating agents) 
 
Pituitary 
Decreased growth hormone, panhypopituitarism (seen with total body 
irradiation) 
 
Pulmonary  
 
Reduced pulmonary function, radiation pneumonitis, pulmonary fibrosis, 
interstitial pneumonitis, restrictive/obstructive lung disease, recurrent 
pneumonia, pleurisy, thymic cysts, bronchiolitis obliterans organizing 
pneumonia (BOOP) 
 
Pulmonary features, particularly pulmonary fibrosis, are most commonly 
associated with chemotherapy (bleomycin, busulfan, CCNU, BCNU, 
cyclophosphamide) and radiation therapy 
 
 
 
Cardiac 
 
Cardiomyopathy, congestive cardiac failure (high association with 
anthracycline chemotherapy), pericarditis (high association with chest 
irradiation), valvular heart disease, coronary arterial disease, premature 
atherosclerosis, impaired myocardial growth 
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Gastrointestinal 
 
Enteric 
Chronic radiation enteropathy, mucosal ulceration, stricture formation, 
malabsorption, tracheoesophageal fistulas (associated with radiotherapy or 
chemotherapy) and bowel obstruction/ileus, volvulus, intussusception, 
adhesions (associated with prior surgical intervention) 
 
Hepatic 
Focal nodular hyperplasia, hemochromatosis (from multiple blood 
transfusions), hepatosteatosis, hepatic fibrosis, hepatic cirrhosis. 
All features can be associated with prior radiotherapy, chemotherapy or 
HSCT 
Urinary 
 
Bladder fibrosis, radiation-induced nephropathy, renal atrophy, end-stage 
renal disease, enterocystic fistulae, acute tubular dysfunction with increased 
excretion of electrolytes, hypophosphatemic rickets (from chemotherapy or 
radiotherapy) 
Musculoskeletal 
 
Leg-length discrepancy, soft-tissue hypoplasia, slipped capital femoral 
epiphyses, pathological fractures from reduced bone mineral density, 
radiation osteitis, short stature, scoliosis, osteochondroma formation, poor 
dental enamel and root formation (associated with radiation therapy, or 
chemotherapy with methotrexate and corticosteroids) 
 
 
BCNU bis-chloroethylnitrosourea 
CCNU 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea 
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Editors’ comments: 
Ed- 1. The reviewers have provided some comments regarding the illustrations and other 
entities that might be included to strengthen the presentation.  Please consider these carefully. 
An illustration or illustrations of chronic pulmonary complications seems conspicuously absent 
and should be added.   
Response: Illustrations of pulmonary fibrosis and cardiomyopathy are now added in the 
manuscript. 
 
Ed- 2.     The discussion of bone growth deformity should be expanded with additional 
illustration(s) and with particular focus on the spine, the pelvis/hips and on the face.  I am not 
sure that I understand the scoliosis case illustrated.  The treated tumor was on the right and 
one would expect the abnormality (undergrowth, fusion) to be on the right not the left – this 
would cause a levoconvex not a dextroconvex curve.  Growth disturbance can be particularly 
problematic for the hips (small acetabulum) and face (dysmorphism).  Should these be 
discussed more?  It would be great to include a slipped capital femoral epiphysis in a post-pelvic 
radiation patient – they are predisposed at younger age. 
Response: Discussion on bone growth disturbances is expanded and imaging examples of major 
abnormalities have been added. The scoliosis case has been replaced with a new case showing 
convexity of the curve opposite to the side of tumor. 
 
Ed- 3.     If you are unable to find these entities at your own institutions, consider obtaining 
them from elsewhere.  I may be able to find a post-RT SCFE image if you do not have one at 
your institutions.  
Response: Thank you! An image of post-RT SCFE is now included. 
 
Ed- 4.     Minor point:  Please change reference numbers in list from superscript to normal font. 
Response: Changes have been made in the manuscript. 
Author's Response to Reviewers' Comments Click here to download Author's Response to Reviewers'
Comments Cover letter 16_00221 R1.docx
Reviewer #1:  
 
Major Weaknesses: Imaging examples of some entities like pulmonary and cardiac 
complications and images for several other entities described in the paper are lacking. 
Response: Imaging examples of most entities are now included. 
 
General Comments:  
 
R#1- 1. In figure 7 legend: please put "long TE" next to or in parenthesis after in-phase and 
"short TE" in parenthesis after out-phase. This is because detection of liver iron on in-phase is 
function of its longer TE compared to out-phase. This is to avoid any confusion as some of the 
currently available 3T scanners are not fast enough to give longer TE in-phase, although 
majority do. 
Response: Thank you for pointing out this important concept. Changes have been made in the 
legend. 
 
R#1- 2. Authors have described many entities representing late complications of cancer 
therapy, but there are comparatively only few imaging examples.  Authors may reduce multiple 
images of a single particular entity and avoid repetitive examples of same entity, to add images 
for other entities if available. 
Response: Changes have been made in multiple figures with addition of a few. 
 
R#1- 3. Some of the references are duplicated, for example reference 74 and 79 are same; 
references 45 and 80 are same. Similarly references 86 and 90 are same. 
Response: Changes have been made in the manuscript. 
 
Reviewer #2:  
R#2- 1.     Very well written article.   
Response: Thank you. 
 
R#2- 2.     At times, the manuscript lacks radiologic detail and reads more like a laundry list of 
complications.   Recommend expanding on description of radiologic findings in some areas 
particularly less common entities and/or if no accompanying illustrative examples (for example, 
those associated with cGVHD including findings that mimic primary sclerosing cholangitis, 
bronchiolitis obliterans as well as in section on pulmonary complications). 
Response: Changes have been made in the manuscript. Imaging example of cGVHD with bile 
duct changes are now included. Bronchiolitis obliterans is already discussed in detail in the first 
article of this series on acute toxicities.  
 
Specific comments:  
 
R#2- 3.     Page 4, line 12: add post treatment to clarify  
Response: Changes have been made in the manuscript. 
 
R#2- 4.     Page 4, line 22: change women to females 
Response: Changes have been made in the manuscript. 
 
R#2- 5.     Page 9: bone tumours section: add sentence or 2 about increased risk of malignant 
bone tumors as well (Roebuck DJ, Radiographics 1999) 
Response: Changes have been made in the manuscript. 
 
R#2- 6.     Figure 1: recommend eliminating figure 1a 
Response: Figure 1a has been removed. Only one figure part (c) has been retained. 
 R#2- 7.     Figure 1: the hypoechoic halo surrounding the solid nodule does suggest a benign 
lesion in the majority of patients (Hoang, Radiographics).  However, it can still be seen in 
neoplastic lesions (Hoang, Radiographics) and is not included in Bonavita’s original description 
of benign nodules which do not require cytologic evaluation (AJR, 2009) 
Response: This discussion is now expanded in the manuscript under thyroid section. 
 
R#2- 8.     Figure 2: recommend eliminating as does not add much value  
Response: Figure 2 has been removed. 
 
R#2- 9.     Figure 3: more figures than necessary, recommend condensing 
Response: Figure part (c) is has been removed. 
 
R#2- 10.     Figure 4: add details to figure legend regarding time frame between treatment and 
development of radiation enteropathy 
Response: Details have been added in the legend. 
 
R#2- 11.     Figure 6: not the best example of hyperintensity on delayed hepatocyte phase MRI 
as difficult to tell if same lesion as those on T2. 
Response: We agree with the reviewer that this is not a great example of hyperintensity of FNH 
in the hepatobiliary phase. A significant number of FNH show isointensity in the hepatobiliary 
phase. The larger lesion is subtly seen and marked in this case. 
 
R#2- 12.     Figure 8: are there pre therapy images of right kidney – consider adding or 
mentioning in figure legend that the right kidney was previously normal 
Response: Unfortunately, could not find the CT imaging at initial presentation. Changes made in 
the figure legend. 
 R#2- 13.     Figure 13: unusual osteochondroma, particularly since no attachment to parent 
bone. Consider using a different example or explain further.  
Response: Unfortunately, coronal images are not available in this case. Please guide us on 
removing this figure.
Reviewer #3:  
R#3- 1. Page 2 line 25 …months and onset is usually not seen after 3 years post-transplant… 
Response: Changes have been made in the manuscript. 
 
R#3- 2. Page 8 line 24 …to differentiate from residual or metastatic bone disease. As irradiated 
bone heals… 
Response: Changes have been made in the manuscript. 
 
Figures: 
 
R#3- 3. It would be nice to show a breast cancer arising within a radiation field, given this is the 
most common solid second malignancy. 
Response: Unfortunately, we could not find an example. 
 
R#3- 4. It would be nice to show a CT of pulmonary fibrosis within a radiation field pattern for 
completeness 
Response: A figure showing pulmonary fibrosis in the radiation field is now included. 
 
R#3- 5. Figure 1 - delete image 1b – redundant 
Response: Figure 1b has been removed. 
 
R#3- 6. Figure 2 - doesn't really add to the presentation – delete 
Response: Figure 2 has been removed. 
 
R#3- 7. Figure 13 - do you have a reformatted image showing the osteochondroma in its 
entirety arising from the adjacent vertebral body/posterior elements.  This would better 
demonstrate your thoughts. 
Response: Unfortunately, we do not have coronal CT reformat or coronal MR image available 
for this case. Please advise us as to whether we can remove this example or not as there is 
already one example of osteochondroma in the figures.  
 
Tables: 
 
R#3- 8. Table 1 - please standardize format for consistency - list diseases followed by etiology, 
or etiology followed by possible resultant diseases (both formats are used in current table)  
Response: Changes have been made in the table. 
 
 
Thank you. 
